Robert Lentz, MD, received funding to test the combination of two drugs in colorectal and pancreas ductal adenocarcinoma. “Metastatic colorectal and pancreas ductal adenocarcinoma are common and deadly and frequently harbor KRAS mutations, novel treatments are desperately needed.”
Thanks to a grant from the Gilead Sciences Research Scholars Program, University of Colorado Cancer Center member Tejas Patil, MD, is launching a study to better understand how persister cells survive in the presence of targeted therapy and what methods might be used to target them to improve patient survival.
In the earliest days of specialized cancer care, either individual oncologists were burdened with the expectation to know everything, or patients were sent on treatment journeys that could involve multiple visits with multiple clinicians in multiple locations. Drs. Lieu and Kim discuss the benefits of multidisciplinary care.